OABI

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. "Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook," stated Matt Foehr, Chief Executive Officer of OmniAb. "Our business at OmniAb continues to strengthen as the reach of our novel technologies expands and as our partnerships become deeper and broade

OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expertise in ion channel discovery and screening. "We are pleased to enter into this important new relationship with Lilly," said Matt Foehr, OmniAb’s Chief Executive Officer. "Lilly is focused on delivering medicines to address major unmet medical needs and our differentiated expertise and established technologies that relate to ion channels are well positioned to

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

Raises Full Year 2026 Revenue and Cash Outlook Driven by Continued Business Momentum Conference Call to Begin Today at 4:30 p.m. ET OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. "We are pleased to report a strong quarter and to increase our revenue and cash outlook for 2026 based on continued momentum in our business. Recent updates from partner programs have been very encouraging with important advancements in clinical deve

4 - OmniAb, Inc. (0001846253) (Issuer)

ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA" or the ", Company", )), an emerging leader in designing novel cancer therapies, today announced the advancement of bispecific ADC (bsADC) program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb, Inc. (NASDAQ:OABI, "OmniAb")). The program is moving into its next collaboration phase with OmniAb's discovery work successfully concluded. VXA-222 utilizes an "AND-gate" logic to address two different target antigens present on solid tumors with one molecule. Established in May 2025, the alliance and joint discovery collaboration brought together OmniAb’s cutting-edge sui

OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on Thursday, August 6, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast What:   OmniAb conference call to discuss second quarter 2026 financial results and business updates       Date:   Thursday, August 6, 2026       Time:   4:30 p.m. E

3 - OmniAb, Inc. (0001846253) (Issuer)

8-K - OmniAb, Inc. (0001846253) (Filer)

OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr. Nwachuku will be primarily responsible for managing the strategy, operations and commercial maximization of xPloration®, OmniAb’s proprietary, innovative high-throughput single B-cell screening platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713808637/en/ Mr. Nwachuku has more than 25 years of experience, including leading m

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

4 - OmniAb, Inc. (0001846253) (Issuer)

8-K - OmniAb, Inc. (0001846253) (Filer)

10-Q - OmniAb, Inc. (0001846253) (Filer)

8-K - OmniAb, Inc. (0001846253) (Filer)

Conference Call Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. "OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidance," stated Matt Foehr, Chief Executive Officer of OmniAb. "Continued progression of partner programs highlights the value of our technology platform and positions our business wel

DEF 14A - OmniAb, Inc. (0001846253) (Filer)

DEFA14A - OmniAb, Inc. (0001846253) (Filer)

OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6th. Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28th. Jefferies Global Healthcare Conference, June 2-4 at the Marriott Marquis in New York City. Management will present a corporate overview on Wednesday, June 3rd at 4:55 p.m. Eastern time and will hold one-on-one meetings with investors

4 - OmniAb, Inc. (0001846253) (Issuer)